Browse Category

NASDAQ:NAMS News 11 October 2025 - 5 January 2026

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

NewAmsterdam Pharma shares fell about 5% to $33.42 in afternoon trading Monday after two insiders filed Form 144 notices for proposed stock sales tied to RSU vesting. CFO M. Ian Somaiya and CSO Johannes Kastelein flagged plans to sell a combined 11,118 shares. The stock touched an intraday low of $32.68. Biotech stocks broadly lagged the market ahead of Friday’s U.S. jobs report.
5 January 2026
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease Newamsterdampharma. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion Newamsterdampharma. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 Newamsterdampharma. Soon after, Dr. Michael Davidson (a leading preventive cardiologist) joined as co-founder and CEO, bringing deep clinical expertise to the leadership team
11 October 2025

Stock Market Today

GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

7 February 2026
GE Vernova shares jumped 5.6% to $779.35 Friday as Wall Street rallied and the company reported 1.1 GW of U.S. wind repower orders for 2025. The company also closed its $5.3 billion purchase of the remaining Prolec GE stake and completed a $2.6 billion senior notes offering. Investors await next week’s U.S. jobs and inflation data.
Citi stock jumps 6% as consent-order exit talk builds — what to watch next week

Citi stock jumps 6% as consent-order exit talk builds — what to watch next week

7 February 2026
Citigroup shares rose 6% to $122.69 at Friday’s close after a Reuters report said executives are more optimistic about completing key consent orders this year. Citi also announced a $2.3 billion preferred stock redemption and a matching program for employee “Trump Accounts.” Investors await next week’s U.S. economic data and Citi conference appearances.
T-Mobile stock price slides into the weekend as Feb. 11 earnings update looms

T-Mobile stock price slides into the weekend as Feb. 11 earnings update looms

7 February 2026
T-Mobile US shares fell 2.2% to $197.39 Friday, underperforming peers ahead of its Feb. 11 earnings and capital markets day. The stock ended 29% below its 52-week high as investors await updated 2026–27 targets from CEO Srini Gopalan. Verizon sued T-Mobile over ad claims, which T-Mobile said it will defend. U.S. jobs and inflation data, delayed by a government shutdown, are due next week.
Go toTop